Last updated: 2026-09-08 07:06:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Nkarta, Inc. (NKTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.92, with a market capitalization of $209.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.70 to $3.72. This page covers its latest market performance, valuation, price trends and company information.
$209.14M | |
$2.75 | |
$79.16 | |
$1.28 | |
$2.79 | |
401.72K | |
660.91K | |
-- | |
$3.72 | |
$1.70 | |
-- | |
-- |
Nkarta, Inc. (NKTX) last closed at $2.79 as of 2026-09-04 23:43:00, unchanged from the previous close of $2.79.
During the latest regular trading session, NKTX traded between $1.28 and $79.16, with a volume of 401.72K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Nkarta, Inc. (NKTX) moved from $2.75 to $2.92, representing a gain of 6.00% ($0.17).
The stock traded between $2.61 and $2.93 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 526.97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 60.1%
NKTX is currently trading at $2.92, placing it 60.1% of the way from its 52-week low of $1.70 to its 52-week high of $3.72. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nkarta, Inc. (NKTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.